Get the Stockscreener App
228.25
0.52%
-1.19
Pre-market:
229.30
1.05
+0.46%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $228.25, with a volume of 1.02M.
It is down -0.52% in the last 24 hours and up +1.69% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$229.44
Open:
$228.19
24h Volume:
1.02M
Relative Volume:
0.72
Market Cap:
$32.93B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
22.00
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+3.77%
1M Performance:
+1.69%
6M Performance:
-1.02%
1Y Performance:
-16.27%
1-Day Range:
$224.26
$229.32
1-Week Range:
$215.80
$234.33
52-Week Range:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
228.25 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
382.29 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
181.85 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.30 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
32.99 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
National Pension Service Has $54.85 Million Stock Position in ResMed Inc. $RMD - MarketBeat
WINTON GROUP Ltd Makes New Investment in ResMed Inc. $RMD - MarketBeat
Why Is ResMed (NYSE:RMD) Suddenly Drawing Attention? - Kalkine Media
ResMed Stock Is Up 13% in Three Months, The Buyback Is Doing the Heavy Lifting. Here’s What It Could Be Worth Before 2027. - TIKR.com
ResMed Inc. stock extends eight-day slide as market value drops - ad-hoc-news.de
ResMed Stock Slides 8.6% Over 8 Straight Down Days - Trefis
ResMed stock heads into the open after a 0.2% dip - ad-hoc-news.de
Is ResMed (ASX:RMD) the Steadier Name in Healthcare? - Kalkine Media
ResMed Inc. stock dips as CEO share sale draws investor attention - ad-hoc-news.de
ResMed CEO Michael J. Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
ResMed CEO Michael Farrell sells $1.11 million of company shares - investing.com
ResMed: A Significant Upside Despite The Perceived Risk (NYSE:RMD) - Seeking Alpha
ResMed CEO Michael Farrell sells $1.11 million of company shares By Investing.com - Investing.com India
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Are Resmed CDI (ASX:RMD) shares good value in 2026? - Rask Media
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Amundi Trims Holdings in ResMed Inc. $RMD - MarketBeat
ResMed stock heads into the open after a 3.3 percent slide - ad-hoc-news.de
Will ResMed Sleep Research Sharpen Its Case (ASX:RMD)? - Kalkine Media
ResMed Inc. stock falls after valuation warning but fundamentals stay solid - ad-hoc-news.de
ResMed Inc. $RMD Shares Purchased by California State Teachers Retirement System - MarketBeat
ResMed (ASX:RMD) Shares Retreat While FY26 Growth Remains in Focus - Kalkine
Resmed Inc Draws Eyes to Healthcare Pathway (ASX:RMD) - Kalkine Media
Is ResMed Inc (RMD) a Bargain After 3.2% Drop? GF Value Says Und - GuruFocus
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Farrell Peter C Disposes of 970 Shares in ResMed at $234.73 Each on September 2, 2026 - Kalkine Media
ResMed Inc. stock slips as Astral halt and GLP-1 worries weigh on sentiment - ad-hoc-news.de
Insider at ResMed (NYSE: RMD) lines up a million-dollar stock sale - Stock Titan
Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know - TradingKey
Saudi Central Bank Increases Position in ResMed Inc. $RMD - MarketBeat
Wellington Management Group LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC - MarketBeat
ResMed Inc. stock heads into the open after a 0.4% dip - ad-hoc-news.de
Why Is ResMed Inc. (ASX:RMD) Drawing Fresh Attention Among Healthcare Stocks? - Kalkine Media
How is ResMed (ASX:RMD) framing its sleep research push? - Kalkine Media
ResMed Inc. stock gains on FY2026 growth and buyback launch - ad-hoc-news.de
ResMed Inc Reports August 2026 CHESS Depositary Interests and Securities Update - Kalkine Media
Paralel Advisors LLC Purchases Shares of 10,293 ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Navigating a 7.78% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc. - MarketBeat
ResMed Inc Discloses August 2026 CDI and Securities Statement - Kalkine
Why Is ResMed (ASX:RMD) Sustaining Home-Care Demand? - Kalkine Media
ResMed Director Peter Farrell Sells 970 Shares Under Rule 10b5-1 Plan - Kalkine
ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentimen - AD HOC NEWS
ResMed Director Peter Farrell Executes Sale of 970 Shares via 10b5-1 Trading Plan - Kalkine Media
ResMed chairman emeritus Peter Farrell sells $227,688 in stock By Investing.com - Investing.com South Africa
ResMed (NYSE:RMD) Director Peter Farrell Sells 970 Shares - MarketBeat
ResMed chairman emeritus Peter Farrell sells $227,688 in stock - investing.com
ResMed (RMD) director sells shares under trading plan - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc.RMD - PR Newswire
Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating - marketscreener.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.15%
2.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):